Search clinical trials for: Edarbi

Total 19 results

University of British Columbia
Canadian Institutes of Health Research (CIHR)

Terminated

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (ARBs CORONA II)

Covid19 | SARS-CoV Infection

Canada, France
Research Institute for Complex Problems of Cardiovascular...

Completed

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus. (AcADEME)

Diabetes Mellitus | Arterial Hypertension | Stable Chronic Angina

Russian Federation
Takeda

Completed

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

Healthy Volunteer

China
Takeda

Completed

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Hypertension

Russian Federation, Kazakhstan
Takeda

Completed

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Essential Hypertension

China
Takeda

Completed

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Type 2 Diabetes Mellitus | Essential Hypertension

Taiwan, Thailand, China
University of Chicago
Takeda

Completed

Effect of Azilsartan on Aldosterone in Postmenopausal Females

Hypertension

United States
Hospital General de México Dr. Eduardo Liceaga

Unknown

Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients

Hypertension | Obesity | Type 2 Diabetes Mellitus

Mexico
Takeda

Completed

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Essential Hypertension

Italy, Poland, Spain, Bulgaria, Serbia, Netherlands, Estonia, Hungary, Germany, Sweden, Lithuania, Slovakia, United Kingdom, France
Takeda

Completed

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Hypertension

Poland, Germany, Bulgaria, Russian Federation, Serbia, Sweden, Netherlands, Estonia, Slovakia, Finland
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
Takeda

Completed

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Argentina, Mexico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Hypertension

United States
Takeda

Completed

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

United States, Mexico, Peru, Brazil, Argentina, Puerto Rico
Takeda

Completed

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Hypertension

United States, Argentina, Peru, Mexico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

Hypertension

United States, Puerto Rico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Hypertension

United States
Takeda

Completed

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Chile, Mexico

3

Subscribe